Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease

Nature Medicine

Volumn 8, Issue 4, 2002, Pages 386-391

  Crute, James J ^a   Grygon, Christine A ^a   Hargrave, Karl D ^a   Simoneau, Bruno ^b   Faucher, Anne Marie ^b   Bolger, Gordon ^b   Kibler, Philip ^b   Liuzzi, Michel ^b   Cordingley, Michael G ^b  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTIVIRUS AGENT; BIC 115 BS; BILS 103 BS; BILS 179 BS; DNA POLYMERASE; DNA PRIMASE; ENZYME INHIBITOR; HELICASE; NUCLEOSIDE ANALOG; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; IC 50; MOROCCO; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; VIROGENESIS; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DNA HELICASES; DNA PRIMASE; DRUG DESIGN; ENZYME INHIBITORS; FEMALE; HERPES GENITALIS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; MICE; MICE, INBRED HRS; PYRIDINES; THIAZOLES; VIRAL PROTEINS;

ANIMALIA; DNA VIRUSES; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; MURINAE; SIMPLEXVIRUS;

EID: 0036107516     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0402-386     Document Type: Article

References (31)

1. Herpes simplex viruses
2. Valacyclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections
3. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir
4. Acyclovir: Mechanism of action and potentiation by ribonucleotide reductase inhibitors
5. Antiviral resistance in clinical practice
6. Herpesvirus DNA replication
7. Replication of herpes simplex virus DNA
8. The structure and function of the HSV DNA replication proteins: Defining novel antiviral targets
9. Herpes simplex virus helicase-primase. Physical and catalytic properties
10. The UL5 gene of herpes simplex virus type 1: Isolation of a lacZ insertion mutant and association of the UL5 gene product with other members of the helicase-primase complex
11. Parallel-compound synthesis: Methodology for accelerating drug discovery
12. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex
13. Frequency of acyclovir-resitant herpes simplex virus in clinical specimens and laboratory isolates
14. Differential effects of famciclovir and valacyclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency
15. Acyclovir treatment of experimental genital herpes simplex virus infections
16. Treatment of recurrent genital herpes simplex infections with oral acyclovir
17. Treatment of recurrent herpes simplex labialis with oral
18. The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture
19. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo
20. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo
21. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome
22. Resistance of herpesviruses to antiviral drugs
23. Analysis of dCMP deaminase and CDP reductase levels in hamster cells infected by herpes simplex virus
24. Overexpression and assembly of the herpes simplex virus type 1 helicase-primase in insect cells
25. Identification of the primase active site of the herpes simplex virus type 1 helicase-primase
26. A DNA helicase induced by herpes simplex virus type 1
27. An improved assay for nanomole amounts of inorganic phosphate
28. Sequence-dependent primer synthesis by the herpes simplex virus helicase-primase complex
29. Cutaneously applied acyclovir acts systemically in the treatment of herpetic infection in the hairless mouse
30. Immune responses to vaginal or systemic infection of BALB/c mice with herpes simplex virus type 2